The Healthcare Technology Report

How DoseMe CEO Paul Edwards is Helping Doctors Dose Smarter When Paul Edwards, the President and Chief Executive Officer of DoseMe, first started working in the medical space, he was struck by the difficulties in using antibiotics to treat patients. “You had these very powerful antibiotics that you knew you couldn't let everybody use,” he said in a 2024 interview, “but at the same time, a physician, because he knew so little about what was happening with the patient, would obviously always choose that big gun antibiotic.” What Edwards realized was that doctors needed to dose smarter, which is the guiding principle behind DoseMe, which he’s run since 2023. In a world where drug development is happening faster and more aggressively than ever, Edwards is working to make sure those drugs are identified and administered to the patients for whom they’re intended, rather than leaving physicians to play guessing games. He analogizes DoseMe’s process to someone attending a sporting event. Broadly speaking, you know where the stadium is, not unlike a doctor would, broadly speaking, be able to identify what could be wrong with a patient. But just as someone attending a football game would need to find their specific seat, DoseMe is designed to help a physician find precisely the right antibiotic with which to treat the patient. DoseMe uses population-based modeling to do this, looking at several medical criteria – age, weight, ethnicity – in conjunction with a Bayesian statistical model, which “gives the clinician very precise information about what dose and for how long and how many times.” By so doing, DoseMe helps speed up every part of the often laborious process of receiving medical treatment, a timesaving effort with a long tail, especially when it comes to vancomycin, a drug used to treat specific bacterial infections. “If you're using trough-based dosing for vancomycin, you need to take blood levels probably every 12 to 24 hours,” Edwards said.”If you're using Bayesian dosing, you take one blood level. You don't take another one. So you're saving on nursing time, you're saving on pharmacy time, and you're getting to your correct dose, your precise dose quicker than you would do with a trough-based dosing methodology, which is what we've used for 30, 40, 50 years.” In enabling doctors to do their best work, Edwards is living his creed. He believes in surrounding himself with smart people and letting them shine – and, critically, he knows when to “get out of the way and let them do what they're good at.” 

Aidoc receives $40 million in debt funding and $110 million in funding from WellSpan Health, Sutter Health, Square Peg Venture Capital Ltd. ,nVentures, Mercy, Hartford HealthCare, and General Catalyst. Aidoc assists physicians in clinical decisions for over 45 million patients a year, helping health systems deliver smarter and faster care when it matters most. Its mission is to transform patient outcomes through "always on" clinical AI, eliminating preventable care gaps that lead to loss of lives and disabilities. To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #venturecapital #clinical #physicians

AbbVie and IGI Sign Global Deal for Trispecific Antibody ISB 2001 To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #pharmaceuticals #biotechnology https://xmrrwallet.com/cmx.plnkd.in/grTxFV-Z

Moderna Gets FDA Approval for Spikevax in Young Children To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #biotechnology #pharmaceuticals #vaccine https://xmrrwallet.com/cmx.plnkd.in/grGUtMSi

Ambience Healthcare receives $243 million in funding from Town Hall Ventures, Smash Capital, Optum Ventures, OpenAI Startup Fund, Oak HC/FT, Kleiner Perkins, Georgian, Frist Cressey Ventures, Founders Circle Capital, and Andreessen Horowitz. Ambience Healthcare is the leading AI platform for documentation, coding, and clinical workflow, built to reduce administrative burden and protect revenue integrity at the point of care. To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #venturecapital #ai #platform

Hala Borno Wants Precision Medicine to Reach Everyone Hala Borno arrived in the U.S. as a refugee of the first Gulf War. She learned English as a second language, navigated the healthcare system alongside her mother during her grandfather’s cancer treatment, and grew up acutely aware of the barriers facing vulnerable communities. She’s spent her career confronting structural gaps in care, first as a physician, then as a researcher, and now as the founder of Trial Library, a company working to dismantle one of the most entrenched inequities in medicine: who gets access to clinical trials. Despite making up the majority of cancer patients in the U.S., people treated in community settings are rarely enrolled in oncology trials. Most research still runs through academic centers, excluding many patients, especially ethnic minorities and underserved populations, from the benefits of precision medicine. “We are at a point in cancer precision medicine where we are seeing miraculous responses to targeted therapies,” Borno has said. “Unfortunately, we are still leaving many patients behind.” Trial Library, launched in 2021 with support from UCSF Innovation Ventures, is built to change that. The platform equips providers with tools to identify relevant trials at the point of care and offers AI-powered navigation to support patients through enrollment. That navigation is designed to surface and address social determinants of health—a core focus of Borno’s academic research. Borno reached out to more than 800 community oncologists across California to understand what was standing in the way. Through those conversations, she recognized that prescreening needed to be worth a physician’s time. Trial Library addressed this by offering sponsor-funded reimbursements to providers—an operational shift that made trial participation more feasible. “Our model is very thoughtful,” Borno explained. “What are the barriers for the medical provider? For the patient?” Today, Trial Library connects more than 1,500 providers across 320 clinics. Borno still holds her role as Associate Professor of Medicine at UCSF, where she has published over 100 peer-reviewed papers and served in leadership roles focused on health equity and community engagement. Her decision to leave academia and build a venture-backed company didn’t come quickly, but it didn’t go away either. “Listen to that hum in the back of your mind,” she’s said. “If it doesn’t go away, do something.” And do something she did.

Leslie Orne Was Headed to Stanford. She Helped Build a Life Sciences Powerhouse Instead. Leslie Orne was packed for Stanford. She’d been accepted to the MBA program and was ready to head west until a conversation with Trinity Life Sciences’ founder changed the plan. “At the last minute the founder of Trinity convinced me to stay and grow the business,” she said. “Here we are today as one of the leading commercial partners to life sciences companies.” That single decision set her on a decades-long path inside Trinity. Orne joined in 2001 as an associate consultant. She’s now CEO of a 1,300-person firm with 12 offices and more than 350 active clients. Along the way, she’s been behind billions in strategic transactions, dozens of drug launches, five acquisitions, and a partnership with Bain & Company. But none of this was preordained. “It is okay to pivot,” Orne has said. “Be open minded—the path won’t always be straight.” Case in point: When she became CEO, she put together a detailed 90-day plan, typical of her years in consulting. Then she scrapped it. The plan was too complex, the timeline too rigid. Instead, she spent her first three months listening—to employees, clients, and the market before making her next move. Orne defines effective leadership as stepping up, offering solutions, and giving people the freedom to own their work. “Lead by example. If you wouldn’t do it, why would they?” she’s said. “Encourage those around you to constantly learn, and to be smarter than you are.” The title doesn’t change who she is, she says: “CEOs are normal people too.” She still watches The Bachelor and listens to Taylor Swift. But the work carries weight. “At Trinity, we live our purpose every day – Every Decision Impacts a Life.”

hims & hers to Expand into Canada in 2026 To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #wellness #fitness https://xmrrwallet.com/cmx.plnkd.in/emmYQhMV

Wysa and RxCap Partner to Improve Medication Adherence Solutions To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #mentalhealth #hospitals #medication https://xmrrwallet.com/cmx.plnkd.in/eb-_kWDX

For AtriCure, Inc.’s Michael Carrel, The Beat Goes On By the end of the decade, Michael Carrel says, Atricure will be a billion-dollar company. As Chief Executive Officer of the Ohio-based business, a position in which he’s served since 2012, Carrel’s big goals also include serving more than 500,000 patients per year and attaining 20 percent probability. Those are lofty benchmarks, but Carrel believes his company will get there. Atricure recently hosted the company’s first investor and analyst day to show how it's pumping new blood into Afib and recovery treatment; in Carrel’s words, they’re “changing standards of care in really critical areas around the world” with innovations including its Isolator Synergy EnCompass Clamp and AtriClip portfolio, now in its third and fourth generations. In so doing, he adds, they’re helping to move Afib treatment forward. “All the clinical evidence that we’re gathering,” Carrel said, “is important to change guidelines and change standards of care.” The investor day was a landmark event for Atricure, just the latest in Carrel’s more than a dozen years at the helm. The Penn State University and Wharton School of Business graduate, who started his professional career as a Certified Public Accountant, has come a long way since his first days as a CEO at Zamba Solutions back in the late ‘90s and has found his forever home at the Cincinnati-area Atricure. Like his company, Carrel isn’t resting on his laurels. He recently visited Washington, DC, to meet with Congress members about “pushing forward” science and policy, then flew to Seattle for the American Association for Thoracic Surgery’s annual meeting, where he talked to field reps and engineers about Atricure’s new FLEX Mini and PRO Mini devices. What he found in his travels, and the company’s All Employee Meeting back in Ohio, is that the beating heart of his company is its employees. “Innovation isn’t just about tech,” he said. “It’s about people showing up with purpose and pushing for progress.” That progress continues, as the company announced in July that it had completed enrollment in its LeAAPS (left atrial appendage exclusion for prophylactic stroke reduction) clinical trial, which Carrel called “an incredible opportunity to drive improved long-term outcomes for patients while significantly expanding our market leadership through the increased use of our AtriClip devices.” This came just three months after the business announced the first successful use of its AtriClip PRO Mini device, which Carrel said is “empowering surgeons with improved visualization and precision.” It’s fitting that, under Carrel’s eye, Atricure’s beat goes on and on.